Selective Phosphodiesterase Inhibitors: A New Therapeutic Option in Inflammation and Autoimmunity

Reumatol Clin. 2016 Nov-Dec;12(6):303-306. doi: 10.1016/j.reuma.2016.07.011. Epub 2016 Aug 25.

[Article in English, Spanish]

Authors

Diana Hernández-Flórez¹, Lara Valor²

Affiliations

¹ Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, España; Instituto de Investigación Biomédica, Hospital Gregorio Marañón, Madrid, España.
² Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, España; Instituto de Investigación Biomédica, Hospital Gregorio Marañón, Madrid, España. Electronic address: lvalor.hgugm@salud.madrid.org.

PMID: 27567299
DOI: 10.1016/j.reuma.2016.07.011

No abstract available

Publication types

Editorial

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
Autoimmune Diseases / drug therapy*
Humans
Inflammation / drug therapy*
Phosphodiesterase 4 Inhibitors / therapeutic use*
Thalidomide / analogs & derivatives*
Thalidomide / therapeutic use
Treatment Outcome

Substances

Anti-Inflammatory Agents, Non-Steroidal
Phosphodiesterase 4 Inhibitors
Thalidomide
apremilast